Prevention of Cervix Cancer in India

Oncology (Switzerland)

Volumn 91, Issue 1, 2016, Pages 1-7

  Mishra, Gauravi A ^a   Pimple, Sharmila A ^a   Shastri, Surendra S ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cervical cancer; HPV vaccine; Prevention; Screening

Indexed keywords

ORAL CONTRACEPTIVE AGENT; WART VIRUS VACCINE; ACETIC ACID; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONCURRENT SEXUAL PARTNERSHIP; EARLY CANCER DIAGNOSIS; FEMALE; HUMAN; INDIA; NONHUMAN; ONSET AGE; ORAL CONTRACEPTIVE USE; PAPANICOLAOU TEST; PARITY; POVERTY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; SMOKING; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS; DEVELOPING COUNTRY; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

ACETIC ACID; DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INDIA; INDICATORS AND REAGENTS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84982833342     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000447575     Document Type: Review

References (46)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, For-man D, Bray F: GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, IARC, 2013. http://globocan.iarc.fr (accessed November 28, 2014).
2. WHO Guidance Note: Comprehensive Cervical Cancer Prevention and Control: A Healthier Future for Girls and Women. WHO, 2013, p 2.
3. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S: Cervical human pap-illomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cy-tological findings. J Infect Dis 2010; 202:1789-1799.
4. IARC: Human papillomaviruses; in: Biological Agents: A Review of Human Carcinogens. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, IARC, 2012, vol 100B. http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11. pdf (accessed September 2014).
5. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL: Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24(suppl 3):S3/26-34.
6. Insinga RP, Dasbach EJ, Elbasha EH, Liaw K, Barr E: Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer 2007; 2: 15.
7. WHO: Weekly Epidemiological Record. Geneva, 2014, No. 43, vol 89, pp 465-492. http://www.who.int/wer/2014/wer8943/en/(accessed October 20, 2014).
8. Denny LA, Francheschi S, de Sanjosé S, Heard I, et al: Human papillomavirus, human immunodeficiency virus and immunosuppres-sion. Vaccine 2012; 30S:F168-F174.
9. Harper DM, Demars LR: Primary strategies for HPV infection and cervical cancer prevention. Clin Obstet Gynecol 2014; 57:256-278.
10. IARC: List of Classifications by Cancer Sites with Sufficient or Limited Evidence in Humans, vol 1-105.
11. International Collaboration of Epidemiologi-cal Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodill A, Green J, Peto J, Plummer M, Sweetland S. Carcinoma of the cervix and tobacco smoking: collaborative re-analysis of individual data on 13, 541 women with carcinoma of the cervix and 23, 017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118:1481-1495.
12. Parkin DM, Boyd L, Walker LC: The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer 2011; 105(S2):S77-S81.
13. Shields TS, Brinton LA, Burk RD, et al: A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus. Cancer Epidemiol Biomarkers Prev 2004; 13: 1574-1582.
14. http://www.cancer.org/cancer/cervicalcancer/moreinformation/cervicalcancerprevention-andearlydetection/cervical-cancer-preven-tion-and-early-detection-toc (accessed December 2, 2014).
15. Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, Surya-kiran P, Thomas F, Struyf F: Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014; 10:1155-1165.
16. Romanowski B: Long term protection against cervical infection with the human papilloma-virus: review of currently available vaccines. Hum Vaccin 2011; 7:161-169.
17. Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, Mehlsen J, Chatterjee A, Iversen OE, Sings HL, Shou Q, Sausser TA, Saah A: Long-term study of a quadrivalent human papilloma virus vaccine. Pediatrics 2014; 134:e657-e665.
18. Schiller JT, Castellsagué X, Garland SM: A review of clinical trials of human papillomavi-rus prophylactic vaccines. Vaccine 2012; 30(suppl 5):F123-F138.
19. Macartney KK, Chiu C, Georgousakis M, Brotherton JM: Safety of human papillomavi-rus vaccines: a review. Drug Saf 2013; 36:393-412.
20. Shastri A, Shastri SS: Cancer screening and prevention in low-resource settings. Nat Rev Cancer 2014; 14:822-829.
21. Dochez C, Bogers JJ, Verhelst R, Rees H: HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine 2014; 32:1595-1601.
22. Adegoke O, Kulasingam S, Virnig B: Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) 2012; 21:1031-1037.
23. Sasieni P, Castanon A, Cuzick J: Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339:b2968.
24. Nygård JF, Skare GB, Thoresen SØ: The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002; 9:86-91.
25. Nanda K, McCrory D, Myers E, Bastian LA, Hasselblad V, Hickey JD, Matchar DB: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132:810-819.
26. http://www.cancerscreening.nhs.uk/cervical/lbc.html (accessed December 3, 2014).
27. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J: Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111:167-177.
28. Nuovo J, Melnikow J, Howell LP: New tests for cervical cancer screening. Am Fam Physician 2001; 64:780-786.
29. Bhatla N, Moda N: The clinical utility of HPV DNA testing in cervical cancer screening strategies. Indian J Med Res 2009; 130:261-265.
30. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Ko-liopoulos G, Dillner J: Chapter 9: Clinical applications of HPV testing: a summary of me-ta-analyses. Vaccine 2006; 24:S78-S89.
31. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hing-mire S, Malvi SG, Thorat R, Kothari A, Chi-noy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA: HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360:1385-1394.
32. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, Lorincz AT: A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9:929-936.
33. Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B: Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4, 136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005; 14: 367-372.
34. Perez Castro S, Iñarrea Fernández A, Lamas González MJ, Sarán Diez MT, Cid Lama A, Alvarez Martín MJ, Pato Mosquera M, López-Miragaya I, Estévez N, Torres Piñón J, Oña Navarro M: Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA. J Med Virol 2013; 85:1063-1068.
35. Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, Terrenato I, Ciccocioppo L, Frega A, Giorgi Rossi P: Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 2011; 49:2643-2650.
36. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M: Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011; 378:1868-1873.
37. Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, Mbalawa CC, Sharma R, Dolo A, Shastri SS, Nacoulma M, Nayama M, Somanathan T, Lucas E, Muwonge R, Frap-part L, Parkin DM: Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer 2004; 110:907-913.
38. Sankaranarayanan R, Shastri SS, Basu P, Mahé C, Mandal R, Amin G, Roy C, Mu-wonge R, Goswami S, Das P, Chinoy R, Frap-part L, Patil S, Choudhury D, Mukherjee T, Dinshaw K: The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neoplasia. Cancer Detect Prev 2004; 28:345-351.
39. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J: Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370:398-406.
40. Shastri SS, Mittra I, Mishra GA, Gupta S, Dik-shit R, Singh S, Badwe RA: Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst 2014; 106:dju009.
41. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Mori-arty AT, Waxman AG, Wilbur DC, Went-zensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee: American Cancer Society, American Society for Colpos-copy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62:147-172.
42. Moyer VA: Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156: 880-891.
43. Committee on Practice Bulletins-Gynecol-ogy: ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol 2012; 120:1222-1238.
44. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. WHO, 2013.
45. Chumworathayi B, Blumenthal PD, Lim-paphayom KK, Kamsa-Ard S, Wongsena M, Supaatakorn P: Effect of single-visit VIA and cryotherapy cervical cancer prevention program in Roi Et, Thailand: a preliminary report. J Obstet Gynaecol Res 2010; 36:79-85.
46. WHO: Prevention of Cervical Cancer through Screening Using Visual Inspection with Acetic Acid (VIA) and Treatment with Cryother-apy. A Demonstration Project in Six African Countries: Malawi, Madagascar, Nigeria, Uganda, the United Republic of Tanzania, and Zambia. WHO, 2012. ISBN 978 92 4 150386 0.